Related Experiment Video
Updated: Dec 29, 2025
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
Inhibiting the Activity of NADPH Oxidase in Cancer
Mariam M Konaté1, Smitha Antony1, James H Doroshow1,2
1Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland, USA.
Abstract:
The primary function of NADPH oxidases (NOX1-5 and dual oxidases DUOX1/2) is to produce reactive oxygen species (ROS). If inadequately regulated, NOX-associated ROS can promote oxidative stress, aberrant signaling, and genomic instability. Correspondingly, NOX isoforms are known to be overexpressed in multiple malignancies, thus constituting potential therapeutic targets in cancer. Multiple genetic studies aimed at suppressing the expression of NOX proteins in cellular and animal models of cancer have provided support for the notion that NOXs play a pro-tumorigenic role. Further, large drug screens and rational design efforts have yielded inhibitor compounds, such as the diphenylene iodonium (DPI) analog series developed by our group, with increased selectivity and potency over "first generation" NOX inhibitors such as apocynin and DPI. The precise role of NOX enzymes in tumor biology remains poorly defined. The tumorigenic properties of NOXs vary with cancer type, and precise tools, such as selective inhibitors, are needed to deconvolute NOX contribution to cancer development. Most NOX inhibitors developed to date are unspecific, and/or their mechanistic and pharmacological characteristics are not well defined. A lack of high-resolution crystal structures for NOX functional domains has hindered the development of potent and selective inhibitors. In-depth studies of NOX interactions with the tumor microenvironment (e.g., cytokines, cell-surface antigens) will help identify new approaches for NOX inhibition in cancer.
Insights
NADPH oxidases (NOX) produce reactive oxygen species (ROS) that can drive cancer. Developing selective NOX inhibitors is crucial for cancer therapy, as current options lack specificity and well-defined characteristics.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- NADPH oxidases (NOX) generate reactive oxygen species (ROS), which, if dysregulated, contribute to oxidative stress, aberrant signaling, and genomic instability.
- Overexpression of NOX isoforms is observed in various malignancies, positioning them as potential therapeutic targets in cancer treatment.
Purpose of the Study:
- To investigate the precise role of NOX enzymes in tumor biology and cancer development.
- To address the limitations of current NOX inhibitors, which often lack specificity and well-defined characteristics.
- To explore novel strategies for NOX inhibition in cancer, including interactions with the tumor microenvironment.
Main Methods:
- Review of genetic studies on NOX protein suppression in cancer models.
- Analysis of drug screening and rational design efforts for NOX inhibitors.
- Discussion of the need for high-resolution crystal structures of NOX functional domains.
- Exploration of NOX interactions with tumor microenvironment components.
Main Results:
- Genetic studies support a pro-tumorigenic role for NOX enzymes in cancer.
- Development of novel diphenylene iodonium (DPI) analog series with improved selectivity and potency over older inhibitors.
- Identification of a need for more specific NOX inhibitors due to varying roles of NOX enzymes across cancer types.
Conclusions:
- The precise role of NOX enzymes in cancer is not fully understood and varies by cancer type.
- Development of selective NOX inhibitors is essential for effective cancer therapy.
- Further research into NOX interactions with the tumor microenvironment may reveal new therapeutic approaches.
Related Concept Videos
02:34Inhibition of Cdk Activity
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:31The Intrinsic Apoptotic Pathway
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:59Cancer Prevention
Some...